Key facts
- Sydnexis’s last known valuation is $90.0M (Aug 2021).
- It has raised $76.5M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Apr 2025.
- Notable investors include RA Capital Management, Longitude Capital, Bluestem Capital Company, Medicxi, SC Master Fund — 6 tracked in total.
- Sydnexis has filed 4 Form Ds with the SEC since 2017, most recently Apr 2025 ($20.0M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Sydnexis
Funding rounds
4 roundsAbout Sydnexis
Developer of a eyecare medicine and drug designed to treat myopia. The company offers a topical eyedrop formulation used to treat the progression of myopia in children, enabling medical professionals and healthcare institutions to control and reduce the number of cases of eye disorders in children effectively.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Del Mar, CA, United States
- Founded
- 2014
- Employees
- 21
- Website
- sydnexis.com/
- Ownership
- Privately Held (backing)
Sydnexis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sydnexis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sydnexis in its N-PORT filings yet. We sweep new filings monthly.